title: Incretin-based therapies for obesity treatment.
abstract: Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.
authors.affiliation: Laboratory of Clinical and Experimental Pathophysiology. Postgraduate Program in Health Sciences at University of Southern Santa Catarina at Tubarão, Santa Catarina, Brazil.
authors.forename: Aline Haas
authors.initials: AH
authors.lastname: de Mello
authors.affiliation: Laboratory of Clinical and Experimental Pathophysiology. Postgraduate Program in Health Sciences at University of Southern Santa Catarina at Tubarão, Santa Catarina, Brazil.
authors.forename: Morgana
authors.initials: M
authors.lastname: Prá
authors.affiliation: Laboratory of Clinical and Experimental Pathophysiology. Postgraduate Program in Health Sciences at University of Southern Santa Catarina at Tubarão, Santa Catarina, Brazil.
authors.forename: Larissa Colonetti
authors.initials: LC
authors.lastname: Cardoso
authors.affiliation: Laboratory of Clinical and Experimental Pathophysiology. Postgraduate Program in Health Sciences at University of Southern Santa Catarina at Tubarão, Santa Catarina, Brazil.
authors.forename: Rosiane
authors.initials: R
authors.lastname: de Bona Schraiber
authors.affiliation: Laboratory of Clinical and Experimental Pathophysiology. Postgraduate Program in Health Sciences at University of Southern Santa Catarina at Tubarão, Santa Catarina, Brazil; Clinical Research Center at Hospital Nossa Senhora da Conceição, Santa Catarina, Brazil. Electronic address: gitezza@hotmail.com.
authors.forename: Gislaine Tezza
authors.initials: GT
authors.lastname: Rezin
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1 / Q000819:agonists; D006801:Humans; D054795:Incretins / Q000502:physiology / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology; D011964:Receptors, Gastrointestinal Hormone / Q000819:agonists / Q000037:antagonists & inhibitors
chemical_list: D019440:Anti-Obesity Agents; D054873:Dipeptidyl-Peptidase IV Inhibitors; D054795:Incretins; D011964:Receptors, Gastrointestinal Hormone; D052216:Glucagon-Like Peptide 1; C041086:gastric inhibitory polypeptide receptor
keywords: DPP-4; GLP-1; Incretin; Obesity; Treatment